Top gatekeeper and CIO exits $12bn Colombian pension fund citywireamericas.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citywireamericas.com Daily Mail and Mail on Sunday newspapers.
BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15)
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health.
Share Article
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
A progressive neurodegenerative disorder, PD is caused by damage to nerve cell in the brain, causing lower dopamine levels. The deterioration of motor and non-motor symptoms is because of dopamine-producing neuron loss.
BlueRock Therapeutics Receives Permission from Health Canada for DA01 Trial in Parkinson s Disease
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced that Health Canada has given permission to initiate Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson s Disease (PD). This is the first trial in Canada to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson s disease. We re excited to initiate this study with our expert collaborators at University Health Network in Toronto as we believe this trial could shift the treatment paradigm for PD patients in Canada and around the world, states Emile Nuwaysir, Ph.D., President and Chief Executive Officer of BlueRock. Our therapy is intended to replace the midbrain dopaminergic neurons lost in the
Targeted pulses of ultrasound can help treat a range of brain diseases
Ultrasound is not only used as an imaging technique but targeted pulses of ultrasound can be used as a highly accurate treatment for a range of brain diseases, for which there were previously only limited treatment options.
Over the last few years, several revolutionary techniques of this kind have been developed, primarily in Toronto but also at MedUni Vienna. The Viennese technique improves brain functions by externally activating neurons that are still functional.
Improvements can be expected in various neuropsychiatric brain diseases such as Alzheimer s, Parkinson s, stroke, Multiple Sclerosis, and neuralgia. A review jointly written by MedUni Vienna and the University of Toronto and published in the specialist journal
Ultrasound in the treatment of brain diseases ANI | Updated: Feb 05, 2021 16:49 IST
Vienna [Austria], February 5 (ANI): Ultrasound is not only used as an imaging technique but targeted pulses of ultrasound can be used as a highly accurate treatment for a range of brain diseases, for which there were previously only limited treatment options.
Over the last few years, several revolutionary techniques of this kind have been developed, primarily in Toronto but also at MedUni Vienna. The Viennese technique improves brain functions by externally activating neurons that are still functional.
Improvements can be expected in various neuropsychiatric brain diseases such as Alzheimer s, Parkinson s, stroke, Multiple Sclerosis, and neuralgia. A review jointly written by MedUni Vienna and the University of Toronto and published in the specialist journal Advanced Science shows that the new treatments are already on the brink of broad clinical applicatio